GSK Likes Its Go-It-Alone Strategy Over A Mega-Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline’s solo strategy is the right one, CEO Andrew Witty said, brushing aside questions about a potential merger with Pfizer during the company’s third quarter sales and earnings call.